This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer; breast cancer	Deoxyuridine triphosphate (dUTP)	<i>In vitro</i> and mouse studies suggest a class of dUTP inhibitors could help treat cancer. Chemical synthesis and <i>in vitro</i> testing of 1,2,3-triazole-containing uracil analogs identified a lead compound as a low nanomolar dUTP inhibitor. In a cancer cell line, the compound and 5-fluorouracil (5-FU) increased cell death compared with either agent alone. In mice with xenograft breast tumors, the compound plus 5-FU was safe and decreased tumor growth compared with either agent alone. Future studies could include testing the lead compound in animal models of other cancers. The generic 5-FU is marketed to treat colorectal, pancreatic and other cancers.	Patented by Taiho Pharmaceutical Co. Ltd.; unavailable for licensing	Miyakoshi, H. <i>et al. J. Med. Chem.</i> ; published online June 20, 2012; doi:10.1021/jm3004174 Contact: Masayoshi Fukuoka, Taiho Pharmaceutical Co. Ltd., Tsukuba, Japan e-mail: m-fukuoka@taiho.co.jp
<i>SciBX</i> 5(27); doi:10.1038/scibx.2012.700 Published online July 12, 2012				